Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsHematopoietic Stem CellsTransplantation, AutologousPeripheral Blood Stem Cell TransplantationTransplantation ChimeraGraft vs Leukemia EffectTissue DonorsMyeloablative AgonistsTreatment OutcomeBone Marrow TransplantationStem CellsBusulfanGraft vs Tumor EffectGraft SurvivalRecurrenceVidarabineHistocompatibility TestingRetrospective StudiesHistocompatibilityLeukemiaWhole-Body IrradiationChimerismRemission InductionLymphocyte TransfusionCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteSiblingsImmunosuppressive AgentsMyelodysplastic SyndromesHematologic DiseasesCytomegalovirus InfectionsPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival RateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSurvival AnalysisHepatic Veno-Occlusive DiseaseCombined Modality TherapyHLA AntigensDisease-Free SurvivalAllograftsMultiple MyelomaMinor Histocompatibility AntigensLymphocyte DepletionTime FactorsSalvage TherapyAcute DiseaseNeoplasm, ResidualAntilymphocyte SerumLiver TransplantationTransplantation ImmunologyT-LymphocytesAnemia, AplasticHematopoietic Stem Cell MobilizationCyclophosphamideFollow-Up StudiesCytomegalovirusTransplantation, IsogeneicAntigens, CD34Opportunistic InfectionsLymphoproliferative DisordersMesenchymal Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsFlow CytometryVirus ActivationMelphalanImmunocompromised HostPrognosisHematopoiesisPrimary MyelofibrosisImmunosuppressionCell TransplantationLeukemia, MyeloidKidney TransplantationBone Marrow CellsRisk FactorsSevere Combined ImmunodeficiencyEmbryonic Stem CellsLeukemic InfiltrationCystitisFatal OutcomeCell DifferentiationCytarabineGanciclovirMice, Inbred C57BLMycosesAntibodies, NeoplasmAdult Stem CellsAntineoplastic AgentsGraft RejectionCyclosporinePyrimidinesBronchiolitis ObliteransProspective StudiesStem Cell NicheChronic Disease